Skip to main content
Journal cover image

(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.

Publication ,  Journal Article
Picozzi, VJ; Ramanathan, RK; Lowery, MA; Ocean, AJ; Mitchel, EP; O'Neil, BH; Guarino, MJ; Conkling, PR; Cohen, SJ; Bahary, N; Frank, RC ...
Published in: Eur J Cancer
September 2015

BACKGROUND: For patients with metastatic pancreatic adenocarcinoma, there are no approved or established treatments beyond the 2nd line. A Phase Ib study of fractionated radioimmunotherapy was undertaken in this setting, administering (90)Y-clivatuzumab tetraxetan (yttrium-90-radiolabelled humanised antibody targeting pancreatic adenocarcinoma mucin) with or without low radiosensitising doses of gemcitabine. METHODS: Fifty-eight patients with three (2-7) median prior treatments were treated on Arm A (N=29, (90)Y-clivatuzumab tetraxetan, weekly 6.5 mCi/m(2)doses×3, plus gemcitabine, weekly 200 mg/m(2) doses×4 starting 1 week earlier) or Arm B (N=29, (90)Y-clivatuzumab tetraxetan alone, weekly 6.5 mCi/m(2)doses×3), repeating cycles after 4-week delays. Safety was the primary endpoint; efficacy was also evaluated. RESULTS: Cytopaenias (predominantly transient thrombocytopenia) were the only significant toxicities. Fifty-three patients (27 Arm A, 26 Arm B, 91% overall) completed ⩾1 full treatment cycles, with 23 (12 Arm A, 11 Arm B; 40%) receiving multiple cycles, including seven (6 Arm A, 1 Arm B; 12%) given 3-9 cycles. Two patients in Arm A had partial responses by RECIST criteria. Kaplan-Meier overall survival (OS) appeared improved in Arm A versus B (hazard ratio [HR] 0.55, 95% CI: 0.29-0.86; P=0.017, log-rank) and the median OS for Arm A versus Arm B increased to 7.9 versus 3.4 months with multiple cycles (HR 0.32, P=0.004), including three patients in Arm A surviving >1 year. CONCLUSIONS: Clinical studies of (90)Y-clivatuzumab tetraxetan combined with low-dose gemcitabine appear feasible in metastatic pancreatic cancer patients beyond 2nd line and a Phase III trial of this combination is now underway in this setting.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Eur J Cancer

DOI

EISSN

1879-0852

Publication Date

September 2015

Volume

51

Issue

14

Start / End Page

1857 / 1864

Location

England

Related Subject Headings

  • Yttrium Radioisotopes
  • United States
  • Treatment Outcome
  • Time Factors
  • Thrombocytopenia
  • Remission Induction
  • Radiopharmaceuticals
  • Radioimmunotherapy
  • Pancreatic Neoplasms
  • Oncology & Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Picozzi, V. J., Ramanathan, R. K., Lowery, M. A., Ocean, A. J., Mitchel, E. P., O’Neil, B. H., … Von Hoff, D. D. (2015). (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. Eur J Cancer, 51(14), 1857–1864. https://doi.org/10.1016/j.ejca.2015.06.119
Picozzi, Vincent J., Ramesh K. Ramanathan, Maeve A. Lowery, Allyson J. Ocean, Edith P. Mitchel, Bert H. O’Neil, Michael J. Guarino, et al. “(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.Eur J Cancer 51, no. 14 (September 2015): 1857–64. https://doi.org/10.1016/j.ejca.2015.06.119.
Picozzi VJ, Ramanathan RK, Lowery MA, Ocean AJ, Mitchel EP, O’Neil BH, et al. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. Eur J Cancer. 2015 Sep;51(14):1857–64.
Picozzi, Vincent J., et al. “(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.Eur J Cancer, vol. 51, no. 14, Sept. 2015, pp. 1857–64. Pubmed, doi:10.1016/j.ejca.2015.06.119.
Picozzi VJ, Ramanathan RK, Lowery MA, Ocean AJ, Mitchel EP, O’Neil BH, Guarino MJ, Conkling PR, Cohen SJ, Bahary N, Frank RC, Dragovich T, Bridges BB, Braiteh FS, Starodub AN, Lee F-C, Gribbin TE, Richards DA, Lee M, Korn RL, Pandit-Taskar N, Goldsmith SJ, Intenzo CM, Sheikh A, Manzone TC, Horne H, Sharkey RM, Wegener WA, O’Reilly EM, Goldenberg DM, Von Hoff DD. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. Eur J Cancer. 2015 Sep;51(14):1857–1864.
Journal cover image

Published In

Eur J Cancer

DOI

EISSN

1879-0852

Publication Date

September 2015

Volume

51

Issue

14

Start / End Page

1857 / 1864

Location

England

Related Subject Headings

  • Yttrium Radioisotopes
  • United States
  • Treatment Outcome
  • Time Factors
  • Thrombocytopenia
  • Remission Induction
  • Radiopharmaceuticals
  • Radioimmunotherapy
  • Pancreatic Neoplasms
  • Oncology & Carcinogenesis